Capstan Therapeutics' CEO Laura Shawver On In Vivo Cell Engineering
Source: Cell & Gene
Capstan Therapeutics' CEO, Laura Shawver, Ph.D., talks us through the company's in vivo CAR therapies and what led to the in vivo cell engineering breakthrough that has been decades in the making. Shawver explains the promise of harnessing mRNA and targeted LNP delivery to train a patient’s body to make CAR-T cells in vivo. She also details best practices to garner funding and investment partnership.
Find Cell & Gene: The Podcast wherever you get your podcasts.
This website uses cookies to ensure you get the best experience on our website. Learn more